LAVA Therapeutics to Present at the Jefferies London Healthcare Conference

Rhea-AI Summary

LAVA Therapeutics, a clinical-stage immuno-oncology company focused on bispecific gamma delta T cell engagers, announced that CEO Stephen Hurly will present at the Jefferies London Healthcare Conference.

The presentation is scheduled for November 17, 2022, from 8:00 a.m. to 8:30 a.m. GMT (3:00 a.m. to 3:30 a.m. EST). A webcast will be available in the investor relations section of their website and archived for 90 days afterward.

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present at the Jefferies London Healthcare Conference.

Presentation Details
Format: Fireside Chat
Date: Thursday, November 17, 2022
Time: 8:00 a.m.-8:30 a.m. GMT / 3:00 a.m.-3:30 a.m. EST

A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at: https://ir.lavatherapeutics.com/news-events/events. A replay will be archived for 90 days following the presentation date.

About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling (NCT05369000). For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.

CONTACTS
Investor Relations
ir@lavatherapeutics.com 

Argot Partners (IR/Media)
212-600-1902
lava@argotpartners.com 

 

FAQ

When is Stephen Hurly's presentation at the Jefferies London Healthcare Conference?

Stephen Hurly's presentation is on November 17, 2022, from 8:00 a.m. to 8:30 a.m. GMT.

How can I watch the LAVA Therapeutics presentation?

The presentation can be watched via a webcast on the investor relations section of the LAVA Therapeutics website.

What is the focus of LAVA Therapeutics?

LAVA Therapeutics focuses on developing bispecific gamma delta T cell engagers for cancer treatment.

What is the ticker symbol for LAVA Therapeutics?

The ticker symbol for LAVA Therapeutics is LVTX.

What is the Gammabody™ platform?

The Gammabody™ platform is utilized by LAVA Therapeutics to develop bispecific gamma delta T cell engagers for cancer therapies.